Longeveron LLC
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; com… Read more
Longeveron LLC (LGVN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.507x
Based on the latest financial reports, Longeveron LLC (LGVN) has a cash flow conversion efficiency ratio of -0.507x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.05 Million) by net assets ($9.97 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Longeveron LLC - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Longeveron LLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Longeveron LLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Longeveron LLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zee Learn Limited
NSE:ZEELEARN
|
0.432x |
|
VAIV Co. Inc.
KQ:301300
|
-0.035x |
|
EcoBio Holdings Co. Ltd
KQ:038870
|
0.027x |
|
Sentien Printing Factory Co Ltd
TWO:8410
|
-0.007x |
|
Sutlej Textiles and Industries Limited
NSE:SUTLEJTEX
|
0.129x |
|
Delta Djakarta Tbk
JK:DLTA
|
0.097x |
|
Murray Cod Australia Ltd
AU:MCA
|
-0.066x |
|
PEPTONIC MEDICAL
F:28L
|
N/A |
Annual Cash Flow Conversion Efficiency for Longeveron LLC (2018–2024)
The table below shows the annual cash flow conversion efficiency of Longeveron LLC from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $21.89 Million | $-13.87 Million | -0.634x | +77.52% |
| 2023-12-31 | $6.74 Million | $-19.00 Million | -2.819x | -313.74% |
| 2022-12-31 | $20.50 Million | $-13.97 Million | -0.681x | -164.81% |
| 2021-12-31 | $37.45 Million | $-9.64 Million | -0.257x | +78.70% |
| 2020-12-31 | $1.96 Million | $-2.36 Million | -1.208x | -124.58% |
| 2019-12-31 | $4.45 Million | $-2.39 Million | -0.538x | +29.22% |
| 2018-12-31 | $6.81 Million | $-5.18 Million | -0.760x | -- |